Clinical Trials
3 trialsNCT07556549 2026-05-22
A Study to Learn About Study Medicine Lorlatinib, as a First-line Treatment in Chinese Adults With ALK-positive a/mNSCLC
Pfizer
Active not recruiting
NCT07567352 2026-05-12
A Study to Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First Treatment
Pfizer
Active not recruiting
NCT06678555 2026-02-05
A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer (NSCLC) Which Has Spread Out.
Pfizer
Active not recruiting